Impax cuts 110 jobs in ongoing Rytary fallout
This article was originally published in Scrip
Executive Summary
Impax Laboratories has cut 110 jobs, mostly at its Hayward, California manufacturing facility to "reduce expenses and adapt to changing market conditions" – i.e. reconsider the company's budget in light of ongoing efforts to comply with US FDA drug-making standards and resubmit a marketing application for the Parkinson's disease drug Rytary (IPX066).